image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 3.55
0.567 %
$ 234 M
Market Cap
-2.57
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STIM stock under the worst case scenario is HIDDEN Compared to the current market price of 3.55 USD, Neuronetics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STIM stock under the base case scenario is HIDDEN Compared to the current market price of 3.55 USD, Neuronetics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STIM stock under the best case scenario is HIDDEN Compared to the current market price of 3.55 USD, Neuronetics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart STIM

image
$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.515 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
74.9 M REVENUE
4.96%
-34.6 M OPERATING INCOME
-13.12%
-43.2 M NET INCOME
-43.11%
-31 M OPERATING CASH FLOW
3.25%
-2.41 M INVESTING CASH FLOW
-82.53%
-6.81 M FINANCING CASH FLOW
-30.00%
22.5 M REVENUE
21.39%
-11.5 M OPERATING INCOME
-48.45%
-12.7 M NET INCOME
4.95%
-8.6 M OPERATING CASH FLOW
-58.69%
-2.38 M INVESTING CASH FLOW
-16971.43%
9.56 M FINANCING CASH FLOW
158.42%
Balance Sheet Neuronetics, Inc.
image
Current Assets 58.1 M
Cash & Short-Term Investments 18.7 M
Receivables 24.3 M
Other Current Assets 15.2 M
Non-Current Assets 82.8 M
Long-Term Investments 86 K
PP&E 33.3 M
Other Non-Current Assets 49.4 M
13.25 %17.24 %10.77 %23.66 %35.03 %Total Assets$140.9m
Current Liabilities 31.3 M
Accounts Payable 11.1 M
Short-Term Debt 4.79 M
Other Current Liabilities 15.4 M
Non-Current Liabilities 77.8 M
Long-Term Debt 22.7 M
Other Non-Current Liabilities 55.2 M
10.15 %4.39 %14.11 %20.79 %50.55 %Total Liabilities$109.1m
EFFICIENCY
Earnings Waterfall Neuronetics, Inc.
image
Revenue 74.9 M
Cost Of Revenue 20.7 M
Gross Profit 54.2 M
Operating Expenses 88.7 M
Operating Income -34.6 M
Other Expenses 8.64 M
Net Income -43.2 M
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)75m(21m)54m(89m)(35m)(9m)(43m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
72.32% GROSS MARGIN
72.32%
-46.15% OPERATING MARGIN
-46.15%
-58.36% NET MARGIN
-58.36%
-157.76% ROE
-157.76%
-31.02% ROA
-31.02%
-30.20% ROIC
-30.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Neuronetics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -43.2 M
Depreciation & Amortization 2.07 M
Capital Expenditures -1.47 M
Stock-Based Compensation 5.6 M
Change in Working Capital 0
Others 4.53 M
Free Cash Flow -32.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Neuronetics, Inc.
image
Wall Street analysts predict an average 1-year price target for STIM of $8 , with forecasts ranging from a low of $8 to a high of $8 .
STIM Lowest Price Target Wall Street Target
8 USD 125.35%
STIM Average Price Target Wall Street Target
8 USD 125.35%
STIM Highest Price Target Wall Street Target
8 USD 125.35%
Price
Max Price Target
Min Price Target
Average Price Target
887766554433221100May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Neuronetics, Inc.
image
Sold
0-3 MONTHS
666 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
94.4 K USD 3
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
260 K USD 2
6-9 MONTHS
103 K USD 1
9-12 MONTHS
7. News
Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression Policy update increases access for millions covered by Evernorth Health Services Policy update increases access for millions covered by Evernorth Health Services globenewswire.com - 1 week ago
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth and cash flow positivity by Q3 2025. seekingalpha.com - 2 weeks ago
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company's press release on March 4, 2025 initially issuing the Company's fourth quarter and full year 2024 financial results (the “Initial Release”) and in connection with finalizing the audited financial statements for the fiscal year ending December 31, 2024, certain non-cash revisions were made to the financial statements related to the Company's acquisition of Greenbrook TMS Inc. (“Greenbrook”) and the shares outstanding in the fourth quarter of 2024. These accounting updates resulted in, among other things: globenewswire.com - 2 weeks ago
Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 3 weeks ago
Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript Neuronetics, Inc. (NASDAQ:STIM ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Max Kruszeski - William Blair Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics Fourth Quarter 2024 Financial and Operating Results Conference Call. seekingalpha.com - 1 month ago
Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. globenewswire.com - 1 month ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. globenewswire.com - 1 month ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 15,750 shares of the Company's common stock (RSUs) to two new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. globenewswire.com - 2 months ago
Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. globenewswire.com - 2 months ago
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All shares in the offering are being offered by the Company. globenewswire.com - 2 months ago
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools globenewswire.com - 2 months ago
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan. globenewswire.com - 3 months ago
8. Profile Summary

Neuronetics, Inc. STIM

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 234 M
Dividend Yield 0.00%
Description Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Contact 3222 Phoenixville Pike, Malvern, PA, 19355 https://www.neurostar.com
IPO Date June 28, 2018
Employees 716
Officers Mr. Rusty Page SVice President & Chief Information and Operations Officer Mr. W. Andrew Macan J.D. Executive Vice President, GC, Chief Compliance Officer & Corporate Secretary Ms. Sara Grubbs Senior Vice President & Chief Revenue Officer Dr. Geoffrey Garland Grammer M.D. Chief Medical Officer Mr. William P. Leonard Chief Clinic Officer Mr. Keith J. Sullivan President, Chief Executive Officer & Director Mr. Stephen J. Furlong M.S. Executive Vice President, Chief Financial Officer & Treasurer Mr. Cory S. Anderson SVice President & Chief Technology Officer Ms. Lisa Metzner-Rosas Senior Vice President & Chief Marketing Officer